Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Protalix Biotherapeutics Inc's Business Segments
Protalix Biotherapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Single Reportable Segment
Total Revenue
$ 34
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Single Reportable Segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | $ 34 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- License and Service78%
- Product22%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License and Service | $ 26 | 78% |
| Product | $ 7 | 22% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Protalix Biotherapeutics Inc
Protalix Biotherapeutics Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel biologic medicines. The company is headquartered in Carmiel, Israel, and was founded in 1993.
Protalix Biotherapeutics is best known for its proprietary ProCellEx protein expression system, which is a unique plant cell-based technology used to produce therapeutic proteins. This system offers advantages over traditional expression systems, such as improved protein stability and enhanced glycosylation patterns. The company has successfully developed several biologic drugs using this platform and continues to exploit its potential for the production of complex proteins.
One of Protalix's most advanced products is taliglucerase alfa (trade name Elelyso), a recombinant glucocerebrosidase enzyme indicated for the treatment of Gaucher disease. Gaucher disease is a rare genetic disorder that causes the accumulation of a fatty substance in cells and various organs, leading to organ dysfunction. Elelyso is the first plant cell-based biologic drug ever approved by the U.S. Food and Drug Administration (FDA) and has been commercialized globally through collaborations with multinational pharmaceutical companies.
In addition to taliglucerase alfa, Protalix has a robust pipeline of potential therapies in various stages of development that target different diseases. Some of the key programs include:
1. PRX-102: A modified version of taliglucerase alfa with improved pharmacokinetic properties for improved dosing convenience.
2. PRX-118: A plant-cell expressed anti-TNF drug candidate for the treatment of inflammatory conditions such as rheumatoid arthritis and Crohn's disease.
3. Oral glucocerebrosidase (PRX-112): A plant-cell-derived oral recombinant enzyme being developed for the treatment of patients with Gaucher disease.
4. Other novel therapeutic candidates: Protalix Biotherapeutics is actively involved in the discovery and preclinical development of innovative biologic drugs for diseases such as Fabry disease, cystic fibrosis, and immune-mediated diseases.
Protalix is also engaged in strategic collaborations and partnerships with major pharmaceutical companies to leverage its ProCellEx technology. These collaborations help in funding research and development efforts, manufacturing capabilities, and global commercialization of their products.
Overall, Protalix Biotherapeutics is a pioneering biopharmaceutical company that is pushing the boundaries of biologic drug development using its unique plant cell-based technology. They are actively working towards bringing novel therapeutic options to patients suffering from various diseases and improving their quality of life.
Protalix Biotherapeutics is best known for its proprietary ProCellEx protein expression system, which is a unique plant cell-based technology used to produce therapeutic proteins. This system offers advantages over traditional expression systems, such as improved protein stability and enhanced glycosylation patterns. The company has successfully developed several biologic drugs using this platform and continues to exploit its potential for the production of complex proteins.
One of Protalix's most advanced products is taliglucerase alfa (trade name Elelyso), a recombinant glucocerebrosidase enzyme indicated for the treatment of Gaucher disease. Gaucher disease is a rare genetic disorder that causes the accumulation of a fatty substance in cells and various organs, leading to organ dysfunction. Elelyso is the first plant cell-based biologic drug ever approved by the U.S. Food and Drug Administration (FDA) and has been commercialized globally through collaborations with multinational pharmaceutical companies.
In addition to taliglucerase alfa, Protalix has a robust pipeline of potential therapies in various stages of development that target different diseases. Some of the key programs include:
1. PRX-102: A modified version of taliglucerase alfa with improved pharmacokinetic properties for improved dosing convenience.
2. PRX-118: A plant-cell expressed anti-TNF drug candidate for the treatment of inflammatory conditions such as rheumatoid arthritis and Crohn's disease.
3. Oral glucocerebrosidase (PRX-112): A plant-cell-derived oral recombinant enzyme being developed for the treatment of patients with Gaucher disease.
4. Other novel therapeutic candidates: Protalix Biotherapeutics is actively involved in the discovery and preclinical development of innovative biologic drugs for diseases such as Fabry disease, cystic fibrosis, and immune-mediated diseases.
Protalix is also engaged in strategic collaborations and partnerships with major pharmaceutical companies to leverage its ProCellEx technology. These collaborations help in funding research and development efforts, manufacturing capabilities, and global commercialization of their products.
Overall, Protalix Biotherapeutics is a pioneering biopharmaceutical company that is pushing the boundaries of biologic drug development using its unique plant cell-based technology. They are actively working towards bringing novel therapeutic options to patients suffering from various diseases and improving their quality of life.
Protalix Biotherapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative recombinant therapeutic proteins. The company is primarily structured around three key segments: proprietary and partnered product candidates, manufacturing and development services, and product royalties and revenues. A detailed look at each segment reveals a multifaceted approach toward addressing significant medical needs, utilizing advanced biotechnological processes.
1. Proprietary and Partnered Product Candidates
Protalix Biotherapeutics invests heavily in the development of both proprietary and partnered therapeutic products, focusing on genetic disorders and various diseases.
Proprietary Product Candidates
One of the central products in Protalixs pipeline is PRX-102 (pegunigalsidase alfa), a genetically engineered form of the enzyme α-galactosidase. PRX-102 is primarily aimed at treating Fabry disease, a rare genetic disorder characterized by the deficiency of this enzyme, leading to the accumulation of globotriaosylceramide in the body. The U.S. FDA and the European Medicines Agency have both granted Orphan Drug Designation to PRX-102, highlighting its importance in treating this under-addressed condition.
Partnered Product Candidates
In addition to its proprietary offerings, Protalix engages in strategic partnerships for the development of additional therapeutic candidates. Notable collaborations include:
- Alidornase alfa: Developed in conjunction with Chiesi Farmaceutici S.p.A. this candidate is being pursued for treating cystic fibrosis, a progressive genetic disease impairing the lungs and digestive system.
- OPRX-106: A treatment for ulcerative colitis, developed in partnership with Oramed Pharmaceuticals Inc. This product aims to address the inflammatory issues associated with this debilitating gastrointestinal condition.
These partnerships leverage Protalixs cutting-edge ProCellEx plant cell-based protein expression system, which enhances the development of complex biologics.
Manufacturing and Development Services
Protalix operates a state-of-the-art manufacturing facility based in Israel, which is integral to its biopharmaceutical operations. The company specializes in:
- Contract Development and Manufacturing Organization (CDMO) services: Protalix offers expertise in the production of recombinant proteins for both clinical trials and commercial use. Utilizing its proprietary ProCellEx platform, the company excels in the efficient and cost-effective manufacturing of therapeutic proteins derived from plant cells. This platform allows for the production of complex biologics that are often challenging to manufacture using traditional methods. Clients in the pharmaceutical sector can benefit from Protalix’s ability to scale production based on specific needs.
Product Royalties and Revenues
The company also generates revenue through a variety of channels, including:
- Product Royalties: Protalix receives royalties based on the net sales of products that are commercialized using its proprietary ProCellEx technology. This arrangement allows Protalix to benefit financially as these products gain traction in the market.
- Collaboration Revenues: Revenue is also generated via licensing and distribution agreements with various pharmaceutical entities. These collaborations may involve upfront payments, milestone payments, and profit-sharing arrangements, providing Protalix with diverse revenue streams beyond its proprietary product candidates.
Conclusion
In summary, Protalix Biotherapeutics Inc. offers a robust array of products and services across its three primary segments. Its commitment to developing proprietary and partnered therapeutic candidates allows it to address critical health needs in rare and genetic diseases. Additionally, the capacity to provide comprehensive manufacturing and development services, coupled with the potential for revenue generation through royalties and collaborations, underscores Protalixs strategic positioning in the biopharmaceutical landscape. Utilizing their innovative ProCellEx technology, Protalix Biotherapeutics aims to be a front-runner in delivering solutions that significantly improve patient outcomes and public health.
1. Proprietary and Partnered Product Candidates
Protalix Biotherapeutics invests heavily in the development of both proprietary and partnered therapeutic products, focusing on genetic disorders and various diseases.
Proprietary Product Candidates
One of the central products in Protalixs pipeline is PRX-102 (pegunigalsidase alfa), a genetically engineered form of the enzyme α-galactosidase. PRX-102 is primarily aimed at treating Fabry disease, a rare genetic disorder characterized by the deficiency of this enzyme, leading to the accumulation of globotriaosylceramide in the body. The U.S. FDA and the European Medicines Agency have both granted Orphan Drug Designation to PRX-102, highlighting its importance in treating this under-addressed condition.
Partnered Product Candidates
In addition to its proprietary offerings, Protalix engages in strategic partnerships for the development of additional therapeutic candidates. Notable collaborations include:
- Alidornase alfa: Developed in conjunction with Chiesi Farmaceutici S.p.A. this candidate is being pursued for treating cystic fibrosis, a progressive genetic disease impairing the lungs and digestive system.
- OPRX-106: A treatment for ulcerative colitis, developed in partnership with Oramed Pharmaceuticals Inc. This product aims to address the inflammatory issues associated with this debilitating gastrointestinal condition.
These partnerships leverage Protalixs cutting-edge ProCellEx plant cell-based protein expression system, which enhances the development of complex biologics.
Manufacturing and Development Services
Protalix operates a state-of-the-art manufacturing facility based in Israel, which is integral to its biopharmaceutical operations. The company specializes in:
- Contract Development and Manufacturing Organization (CDMO) services: Protalix offers expertise in the production of recombinant proteins for both clinical trials and commercial use. Utilizing its proprietary ProCellEx platform, the company excels in the efficient and cost-effective manufacturing of therapeutic proteins derived from plant cells. This platform allows for the production of complex biologics that are often challenging to manufacture using traditional methods. Clients in the pharmaceutical sector can benefit from Protalix’s ability to scale production based on specific needs.
Product Royalties and Revenues
The company also generates revenue through a variety of channels, including:
- Product Royalties: Protalix receives royalties based on the net sales of products that are commercialized using its proprietary ProCellEx technology. This arrangement allows Protalix to benefit financially as these products gain traction in the market.
- Collaboration Revenues: Revenue is also generated via licensing and distribution agreements with various pharmaceutical entities. These collaborations may involve upfront payments, milestone payments, and profit-sharing arrangements, providing Protalix with diverse revenue streams beyond its proprietary product candidates.
Conclusion
In summary, Protalix Biotherapeutics Inc. offers a robust array of products and services across its three primary segments. Its commitment to developing proprietary and partnered therapeutic candidates allows it to address critical health needs in rare and genetic diseases. Additionally, the capacity to provide comprehensive manufacturing and development services, coupled with the potential for revenue generation through royalties and collaborations, underscores Protalixs strategic positioning in the biopharmaceutical landscape. Utilizing their innovative ProCellEx technology, Protalix Biotherapeutics aims to be a front-runner in delivering solutions that significantly improve patient outcomes and public health.